Skip to main content
UnicoCell logo

UnicoCell — Investor Relations & Filings

Ticker · 6794 ISIN · TW0006794001 TW Professional, scientific and technical activities
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-04-30 Annual Report
Country TW Taiwan
Listing TW 6794

About UnicoCell

https://www.unicocell.com

UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.

Recent filings

Filing Released Lang Actions
114年年報及股東會資料 — 2025_6794_20260520FE4.pdf
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' and contains detailed sections typical of an annual report, including a report to shareholders, corporate governance report, financial performance analysis, business overview, R&D achievements, and future business plans. It includes comprehensive financial data, management discussion, and strategic outlook for the company. The length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. The presence of detailed financial statements and extensive narrative confirms it is the full annual report rather than an announcement or a supplementary document.
2026-04-30 English
114年年報及股東會資料 — 2025_6794_20260520F04.pdf
Annual Report Classification · 98% confidence The document is titled as the "114年度年報" which translates to the "Annual Report for the year 114" (Taiwanese calendar year corresponding to 2025). It contains detailed sections typical of an annual report, including a shareholder letter, company governance report, financial results, business overview, research and development updates, and future outlook. The document includes comprehensive financial data such as revenue, net loss, earnings per share, and detailed management discussion. It also includes governance information but the primary content is the full annual report with financial performance and operational details. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-30 Chinese
114年第4季財務報告書 — 202504_6794_AIB.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Financial Statements and Independent Auditors’ Report December 31, 2025 and 2024' for Unicocell Biomed Co., Ltd. It contains an independent auditor's opinion, basis for opinion, key audit matters, management responsibilities, and detailed financial statements including balance sheets and statements of comprehensive income for the years ended December 31, 2025 and 2024. The content is comprehensive, includes actual financial data, and is clearly the full audit report and financial statements rather than a brief announcement or certification. The presence of detailed notes, audit procedures, and financial figures confirms this is a standalone audit report document. Therefore, the appropriate classification is Audit Report / Information (AR).
2026-04-29 Chinese
114年第4季財務報告書 — 202504_6794_AI2.pdf
Annual Report Classification · 100% confidence The document is titled as a financial report and auditor's report for the fiscal years 114 and 113 (Taiwanese calendar years), which correspond to a full annual period. It includes detailed financial statements such as the balance sheet, income statement, statement of changes in equity, cash flow statement, and notes to the financial statements. It also contains the auditor's opinion and basis for the audit, key audit matters, management responsibilities, and auditor responsibilities. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. The presence of the auditor's report integrated with the financial statements and notes confirms this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-29 Chinese
114年第4季財務報告書 — 202503_6794_AI2.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a financial report and auditor's review report for the third quarter of years 114 and 113 (Taiwanese calendar years), which corresponds to an interim period. It includes detailed financial statements such as the balance sheet, income statement, statement of changes in equity, cash flow statement, and notes to the financial statements. The auditor's review report references the application of International Accounting Standard 34 "Interim Financial Reporting" and states that the financial statements have been reviewed, not audited, which is typical for interim or quarterly reports. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document is a comprehensive interim/quarterly financial report containing substantive financial data and analysis for a period shorter than a full fiscal year.
2026-04-29 Chinese
114年第4季財務報告書 — 202502_6794_AI2.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a financial report and an auditor's review report for the second quarter of years 114 and 113 (Taiwanese calendar years). It includes detailed financial statements such as the balance sheet, income statement, statement of changes in equity, cash flow statement, and notes to the financial statements. The presence of an auditor's review report (會計師核閱報告) indicates it is a reviewed interim financial report rather than a full annual report. The document covers a half-year period and contains substantive financial data and analysis, consistent with an Interim / Quarterly Report. It is not merely an announcement or certification but a full financial report with auditor review. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-04-29 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.